Industry News
Excerpt from the Press Release: National Health Care Institute of the Netherlands-supported study to evaluate role of the HeartFlow Analysis in reducing unnecessary invasive procedures REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that physicians at Erasmus MC Hospital (Rotterdam NL) have enrolled the first three patients in the…
Read More
Excerpt from the Press Release: First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil. Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month. SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal…
Read More
Tantu will leverage Ginkgo’s foundries to accelerate strain construction as a key step toward human clinical trials Excerpt from the Press Release: BOSTON, Sept. 7, 2021 /PRNewswire/ — Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks (“Ginkgo”), which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the…
Read More
Excerpt from the Press Release: RINCETON, N.J.–(BUSINESS WIRE)–The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in the…
Read More
Excerpt from the Press Release: One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE…
Read More
Excerpt from the Press Release: Collaboration Under BARDA DRIVe Solving Sepsis Program to also Support Key Regulatory Path Activities to Advance Development of SBI-101 Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the…
Read More
-IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing- Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated…
Read More
Excerpt from the Press Release: Stanford University is expanding its free repository of imaging and healthcare datasets for artificial intelligence researchers around the globe. The California school’s Center for Artificial Intelligence in Medicine and Imaging first opened in 2019 and has since amassed annotated datasets for more than 1 million images. AIMI is now partnering…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ: LWAC). The resulting combined company (the Company) has been renamed “eFFECTOR Therapeutics, Inc.” and…
Read More